lapatinib has been researched along with Experimental Neoplasms in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Affleck, K; Alligood, KJ; Gilmer, TM; Keith, BR; Knight, WB; Lackey, K; Mullin, RJ; Murray, DM; Rhodes, N; Rusnak, DW; Wood, ER | 1 |
| Acton, DG; Ballard, P; Barlaam, B; Bradbury, RH; Cross, D; Ducray, R; Germain, H; Hudson, K; Klinowska, T; Magnien, F; Ogilvie, DJ; Olivier, A; Ross, HS; Smith, R; Trigwell, CB; Vautier, M; Wright, L | 1 |
| Bailey-Downs, LC; Bastian, A; Disch, BC; Dybdal-Hargreaves, NF; Gangjee, A; Hamel, E; Ihnat, M; Mooberry, SL; Raghavan, S; Rohena, CC; Thorpe, JE; Zhang, X | 1 |
| Abouzid, KAM; Esmat, A; Hossam, M; Ismail, NSM; Lasheen, DS; Mansour, AM; Singab, ANB | 1 |
| Fan, C; Guo, Z; Li, Y; Lin, D; Yang, S; Yang, Y; Zhang, L; Zhao, S; Zhu, J | 1 |
| Casanovas, O; Castillo-Ávila, W; Condom, E; Garcia Del Muro, X; Germà, JR; Graupera, M; Hernández-Losa, J; Juliachs, M; Pandiella, A; Piulats, JM; Teixidó, C; Vidal, A; Villanueva, A; Viñals, F | 1 |
6 other study(ies) available for lapatinib and Experimental Neoplasms
| Article | Year |
|---|---|
The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Cycle; Cell Division; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Female; Fibroblasts; Furans; Humans; Infant, Newborn; Mice; Mice, Nude; Mice, SCID; Neoplasms, Experimental; Phosphorylation; Precipitin Tests; Quinazolines; Receptor, ErbB-2; Signal Transduction; Skin; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2001 |
Neutral 5-substituted 4-indazolylaminoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Dogs; Epidermal Growth Factor; ErbB Receptors; Ether-A-Go-Go Potassium Channels; Female; Hepatocytes; Humans; Indazoles; Keratinocytes; Lapatinib; Male; Metabolic Clearance Rate; Mice; Mice, Nude; Mice, SCID; Microsomes; Molecular Structure; Neoplasms, Experimental; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Rats; Rats, Wistar; Receptor, ErbB-2; Survival Rate; Xenograft Model Antitumor Assays | 2008 |
The design and discovery of water soluble 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multitargeted receptor tyrosine kinase inhibitors and microtubule targeting antitumor agents.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Female; HeLa Cells; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Microtubules; Neoplasms, Experimental; Protein Kinase Inhibitors; Pyrimidines; Receptor Protein-Tyrosine Kinases; Solubility; Structure-Activity Relationship; Water | 2014 |
Discovery of anilino-furo[2,3-d]pyrimidine derivatives as dual inhibitors of EGFR/HER2 tyrosine kinase and their anticancer activity.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; ErbB Receptors; Female; Humans; Mice; Molecular Structure; Neoplasms, Experimental; Protein Kinase Inhibitors; Pyrimidines; Structure-Activity Relationship; Tumor Cells, Cultured | 2018 |
Discovery of a potent dual EGFR/HER-2 inhibitor L-2 (selatinib) for the treatment of cancer.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; ErbB Receptors; Female; Humans; Lapatinib; Male; Mice; Mice, Inbred BALB C; Molecular Structure; Neoplasms; Neoplasms, Experimental; Quinazolines; Rats; Rats, Wistar; Receptor, ErbB-2; Solubility; Structure-Activity Relationship | 2013 |
ErbBs inhibition by lapatinib blocks tumor growth in an orthotopic model of human testicular germ cell tumor.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Blotting, Western; Carcinoma, Embryonal; Cell Survival; Cetuximab; Choriocarcinoma; Endodermal Sinus Tumor; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Immunoprecipitation; Lapatinib; Male; Mice; Mice, Nude; Neoplasms, Experimental; Neoplasms, Germ Cell and Embryonal; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Real-Time Polymerase Chain Reaction; Receptor, ErbB-2; Receptor, ErbB-3; Teratocarcinoma; Testicular Neoplasms; Transplantation, Heterologous | 2013 |